Vimarsana
Biggest News Aggregation in the World

Page 35 - Rapid Acceleration News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rapid Acceleration. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rapid Acceleration Today - Breaking & Trending Today

Guilford company targeting 'unprecedented demand' with its at-home COVID test - Vimarsana News

Guilford company targeting 'unprecedented demand' with its at-home COVID test

Detect’s COVID-19 Test is undergoing U.S. Food and Drug Administration review.

Detect™ Selected by NIH to Scale Manufacturing of PCR-Quality Rapid At-Home Covid-19 Test - Vimarsana News

Detect™ Selected by NIH to Scale Manufacturing of PCR-Quality Rapid At-Home Covid-19 Test

Detect™, Inc., a Connecticut-based health technology company, announced today that the National Institutes of Health (NIH) has selected the Detect™ Covid-19 Test to receive funding from the highly competitive Rapid Acceleration of Diagnostics Initiative (RADxSM).

Source: nih.gov
LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & Flu A/B Rapid Antigen Test - Vimarsana News

LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & Flu A/B Rapid Antigen Test

/PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostic company, today announced it has submitted the LumiraDx SARS-CoV-2 & Flu A/B...

Biomarkers May indicate Severity of COVID in Children - Vimarsana News

Biomarkers May indicate Severity of COVID in Children

Biomarkers detected in saliva samples could be potential indicators of disease severity in children with COVID, new research shows.

NIH RADx initiative expands COVID-19 testing innovation for additional types of rapid tests - Vimarsana News

NIH RADx initiative expands COVID-19 testing innovation for additional types of rapid tests

The NIH RADx initiative announced today that it has issued contract awards totaling $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19. The home and point-of-care testing platforms target the need for high-performance, low-cost home tests and point-of-care tests that can potentially detect multiple respiratory infections.

Source: nih.gov